Jagath R Junutula
Nature Biotechnology · 2008–2013
A researcher in the Science corpus: 3 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Who trusts Jagath R Junutula overall
Papers from Jagath R Junutula's perspective
Ordered by how strongly the researchers Jagath R Junutula trusts endorse each paper. Same corpus, a different order for every researcher.
- Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (Nature Biotechnology)
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
- Targeted cancer therapy: conferring specificity to cytotoxic drugs. (Accounts of Chemical Research)
- Monoclonal antibody successes in the clinic (Nature Biotechnology)
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
- A history of cancer chemotherapy. (Cancer Research)
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (Nature Biotechnology)
- An enhanced system for unnatural amino acid mutagenesis in E. coli. (Journal of Molecular Biology)
- Antibody Drug Conjugates for Cancer Therapy (Pharmacological Reviews)
Their papers
- Site-specific antibody drug conjugates for cancer therapy (2013) — 623 citations
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012) — 928 citations
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008) — 1,242 citations